Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab

Saskia JAM Santegoets; Anita GM Stam; Sinéad M Lougheed; Helen Gall; Karin Jooss; Natalie Sacks; Kristen Hege; Israel Lowy; Rik J Scheper; Winald R Gerritsen; Alfons JM van den Eertwegh; Tanja D de Gruijl

doi:10.1186/s40425-014-0031-3

Article info

Research Article

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab

Free

Authors

Saskia JAM Santegoets Department of Medical OncologyVU University Medical Center, Cancer Center Amsterdam Amsterdam The Netherlands PubMed articles Google scholar articles
Anita GM Stam Department of Medical OncologyVU University Medical Center, Cancer Center Amsterdam Amsterdam The Netherlands Department of PathologyVU University Medical Center, Cancer Center Amsterdam Amsterdam The Netherlands PubMed articles Google scholar articles
Sinéad M Lougheed Department of Medical OncologyVU University Medical Center, Cancer Center Amsterdam Amsterdam The Netherlands PubMed articles Google scholar articles
Helen Gall Department of Medical OncologyVU University Medical Center, Cancer Center Amsterdam Amsterdam The Netherlands PubMed articles Google scholar articles
Karin Jooss Cell Genesys Inc South San Francisco CA USA PubMed articles Google scholar articles
Natalie Sacks Cell Genesys Inc South San Francisco CA USA PubMed articles Google scholar articles
Kristen Hege Cell Genesys Inc South San Francisco CA USA PubMed articles Google scholar articles
Israel Lowy Medarex, Bloomsbury, NJ/Bristol-Myers Squibb Company Wallingford CT USA PubMed articles Google scholar articles
Rik J Scheper Department of PathologyVU University Medical Center, Cancer Center Amsterdam Amsterdam The Netherlands PubMed articles Google scholar articles
Winald R Gerritsen Department of Medical OncologyVU University Medical Center, Cancer Center Amsterdam Amsterdam The Netherlands PubMed articles Google scholar articles
Alfons JM van den Eertwegh Department of Medical OncologyVU University Medical Center, Cancer Center Amsterdam Amsterdam The Netherlands PubMed articles Google scholar articles
Tanja D de Gruijl Department of Medical OncologyVU University Medical Center, Cancer Center Amsterdam Amsterdam The Netherlands PubMed articles Google scholar articles

↵a s.j.a.m.santegoets{at}lumc.nl
↵b agm.stam{at}vumc.nl
↵c sm.lougheed{at}vumc.nl
↵d h.gall{at}vumc.nl
↵e Karin.Jooss{at}pfizer.com
↵f nsacks{at}onyx-pharm.com
↵g khege{at}celgene.com
↵h Israel.lowy{at}regeneron.com
↵i rj.scheper{at}vumc.nl
↵j W.Gerritsen{at}onco.umcn.nl
↵k vandeneertwegh{at}vumc.nl
↵l td.degruijl{at}vumc.nl

View Full Text

Citation

Santegoets SJ, Stam AG, Lougheed SM, et al

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab

Journal for ImmunoTherapy of Cancer 2014;2:31. doi: 10.1186/s40425-014-0031-3

Publication history

Received April 9, 2014
Accepted August 6, 2014
First published September 16, 2014.

Online issue publication

February 09, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password